BIO logo

BIO-RAD LABORATORIES-A

BIONYSE
๐Ÿ† #798 by market capEarnings Nov 4 ยท PostUS Equity
$385.27โ–ฒ $4.34 (+1.14%)
After hours ยท at close
๐Ÿ””
Track BIO
Get earnings, price moves & breaking news on Telegram
Track
24hโ–ฒ 1.1%
7dโ–ฒ 7.0%
14dโ–ฒ 6.3%
30dโ–ฒ 2.1%
ytdโ–ฒ 26.9%
1yโ–ฒ 16.9%
๐ŸฆMarket Cap
$10.30B
Mid Cap
๐Ÿ“ˆRevenue Growth (YoY)
1.4%
Slowing
๐Ÿ“ŠGross Margin
51.9%
Healthy
๐Ÿ’ตFCF Margin
13.6%
Healthy
โš–๏ธP/S Ratio
3.9x
Fair
Otter Score
โ€”
Insufficient data

Trading Snapshot

Day Range
$380.42 โ€“ $388.02
52-Week Range
$236.73 โ€“ $396.23
Volume (shares)
14,390
Avg Volume (shares)
โ€”
Shares Outstanding
26.7M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
โ€”
Last Q Revenue
โ€”
P/E Ratio
45.9
P/S Ratio
3.9x
EPS (TTM)
$8.25
Dividend Yield
โ€”
BIO logo

BIO-RAD LABORATORIES-A

BIO
Financial Trends

Financial history unavailable.

StockOtter ยท stockotter.space

About BIO-RAD LABORATORIES-A

Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical schools), industrial research organizations, government agencies, pharmaceutical companies, biotechnology firms, food producers, and food testing laboratories. In contrast, the Clinical Diagnostics division designs, produces, sells, and supports a comprehensive suite of test systems, informatics solutions, diagnostic kits, and specialized quality control products for clinical laboratories. This segment provides reagents, instruments, and software specifically tailored for particular niches within the in vitro diagnostics market. Its customer base includes reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. Beyond these core segments, Bio-Rad also offers systems and products designed to separate complex chemical and biological materials, as well as to identify, analyze, and purify their individual components. The company distributes its extensive product portfolio through a combination of its direct sales force and a network of third-party distributors, agents, brokers, and resellers.

๐Ÿฆฆ

Otter Score Breakdown

How it's scoredFive components, each rated 1โ€“5โ˜… and equally weighted (20%), averaged to a 0โ€“100 score:๐Ÿ’Ž Quality โ€” gross margin๐Ÿš€ Growth โ€” revenue YoYโš–๏ธ Valuation โ€” P/S ratioโšก Momentum โ€” 30-day price change๐Ÿ’ง Dilution โ€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

๐Ÿ’ŽQualityโ˜…โ˜…โ˜…โ˜…โ˜…
๐Ÿš€Growthโ˜…โ˜…โ˜…โ˜…โ˜…
โš–๏ธValuationโ˜…โ˜…โ˜…โ˜…โ˜…
โšกMomentumโ˜…โ˜…โ˜…โ˜…โ˜…
Overall Score
Insufficient data
โ€”/100
Analyst data unavailable.

Latest News & Updates

News unavailable.